Speedel Could Market Blood Clot Candidate On Its Own
This article was originally published in The Pink Sheet Daily
Executive Summary
After Abbott announces it will not exercise a license-back option, the Swiss firm is considering several options.
You may also be interested in...
Tekturna Launch Anticipated “Very Quickly” Following Approval
Novartis has recruited an additional 1,000 sales reps in preparation for the launch of the antihypertensive, according to partner Speedel.
Tekturna Launch Anticipated “Very Quickly” Following Approval
Novartis has recruited an additional 1,000 sales reps in preparation for the launch of the antihypertensive, according to partner Speedel.
Novartis/Speedel Anti-Hypertensive Rasilez Could Reach Market By Year-End
NDA for the oral renin inhibitor, submitted in the first quarter, seeks monotherapy and combination treatment claims.